Hypoglycemia at the time of Covid-19 pandemic
| dc.creator | Shah, Kiran | |
| dc.creator | Tiwaskar, Mangesh | |
| dc.creator | Chawla, Purvi | |
| dc.creator | Kale, Mayura | |
| dc.creator | Deshmane, Rajesh | |
| dc.creator | Sowani, Alpana | |
| dc.date.accessioned | 2020-08-21T16:03:24Z | |
| dc.date.available | 2020-08-21T16:03:24Z | |
| dc.date.created | 2020 | |
| dc.description.abstract | Background: Hypoglycemia is the limiting factor in the glycemic management of diabetes, which need to be addressed critically to avoid complications. Lockdown because of new coronavirus strain (COVID-19) pandemic has further complicated the issue of hypoglycemia due to limitations in access to food, outpatient clinics, pathological services and medicines. Aim: To assess the factors associated with the risk of hypoglycemia during AprileMay 2020 lockdown in people with type 2 diabetes mellitus. Methodology: We analyzed the data retrospectively from 146 patients of type 2 diabetes mellitus (T2DM) reporting to the emergency department (ED) during lockdown period with symptoms suggestive of hypoglycemia. Results: The majority of patients were male (90/146) with a mean age of 59.88 ± 10.09 years and a mean random blood glucose level of 57.67 ± 9.00 mg/dL. Two-third of patients (70.83%) had level 1 hypoglycemia, while level 2 hypoglycemia was reported in 29.16% of patients. A combination of Metformin and Sulfonylureas (SU) was most commonly associated with the risk of hypoglycemia (65.75%) followed by insulin (33.56%). Subjects who received insulin reported a lower blood glucose value (50.75 ± 8.20 mg/dL) as compared to those receiving a combination of metformin and SU (60.95 ± 7.10 mg/dl). 330.56% of patients who had received prophylaxis hydroxychloroquine (HCQ) 400 mg twice a day along with the routine anti-hyperglycemic agents without their dose adjustment reported hypoglycemia. Patients with hypertension, micro-vascular, macro-vascular complications, and coexistent with each other had a higher propensity to the risk of hypoglycemia (46.58%, 33.56%, 23.29%, and 32.88%) respectively. Conclusion: The COVID-19 lockdown has shown to influence the risk of hypoglycemia in patients with T2DM, especially those receiving SU, insulin, HCQ especially in patients with associated co-morbidities. Patient education, support, and telemedicine plays a pivotal role to prevent hypoglycemia | spa |
| dc.format.extent | 4 páginas | spa |
| dc.format.mimetype | image/jepg | spa |
| dc.identifier.doi | https://doi.org/10.1016/j.dsx.2020.07.003 | spa |
| dc.identifier.other | https://doi.org/10.1016/j.dsx.2020.07.003 | spa |
| dc.identifier.uri | https://hdl.handle.net/20.500.12010/12087 | |
| dc.language.iso | eng | spa |
| dc.publisher | Diabetes & Metabolic Syndrome: Clinical Research & Reviews | spa |
| dc.rights.accessrights | info:eu-repo/semantics/embargoedAccess | spa |
| dc.rights.local | Acceso restringido | spa |
| dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
| dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
| dc.subject | Hypoglycemia | spa |
| dc.subject | Anti-diabetic agents | spa |
| dc.subject | COVID-19 | spa |
| dc.subject | Comorbidities | spa |
| dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
| dc.subject.lemb | COVID-19 | spa |
| dc.subject.lemb | SARS-CoV-2 | spa |
| dc.subject.lemb | Coronavirus | spa |
| dc.title | Hypoglycemia at the time of Covid-19 pandemic | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.type.local | Artículo | spa |
Archivos
Bloque original
1 - 2 de 2
Cargando...
- Nombre:
- Captura.PNG
- Tamaño:
- 178.9 KB
- Formato:
- Portable Network Graphics
- Descripción:
- Ver portada
Cargando...
- Nombre:
- Hypoglycemia-at-the-time-of-Cov_2020_Diabetes---Metabolic-Syndrome--Clinical.pdf
- Tamaño:
- 225.74 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Artículo reservado
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 2.87 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción:
